As of Sep 30, 2024, United Therapeutics Corporation's fair value using the Ben Graham formula is $825.9 per share. This is calculated using Ben Graham formula, where EPS is $24.3 and BVPS (Book Value Per Share) is $133.5. The current price of $365.0 suggests United Therapeutics Corporation may be overvalued by this conservative metric.
United Therapeutics Corporation earnings per share (EPS) for the twelve months ending Sep 30, 2024, was $24.3, a 15.5% growth year-over-year.
United Therapeutics Corporation's margin of safety is positive 126.3%, calculated as (Graham Number - Current Price) / Current Price. A negative margin of safety suggests the stock doesn't provide the level of safety Graham typically sought in his investments.